{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:11Z","timestamp":1789154411055,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN) which can progress to myelofibrosis (MF), a phenomenon termed post-PV MF. Ruxolitinib is a Janus activated kinase (JAK) inhibitor that targets JAK1\/2 mutations and is approved for treatment of high-risk MF. This is a case report of a patient with post-PV MF who developed acute psychotic disorder five months after commencing ruxolitinib and whose mental status returned to baseline within one week of stopping ruxolitinib. Importantly, there was no history of mental health disorder and no identifiable triggers for his presentation. Ruxolitinib has not previously been implicated in the development of psychosis but is known to cross the blood-brain barrier and affect multiple cell signalling pathways within the central nervous system. Together, this makes an association between ruxolitinib and neuropsychiatric symptoms plausible, yet further understanding of causal mechanisms is warranted.<\/jats:p>","DOI":"10.1007\/s00277-026-06764-0","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:51:03Z","timestamp":1769125863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute psychosis following initiation of ruxolitinib in post-polycythaemia vera myelofibrosis case report"],"prefix":"10.1007","volume":"105","author":[{"given":"Louise Jade","family":"Potter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mansour","family":"Ceesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"1","key":"6764_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 world health organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14\u201322","journal-title":"Leukemia"},{"key":"6764_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumours of Haematopoietic and lymphoid tissues. International agency for research on cancer Lyon, France"},{"issue":"2","key":"6764_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJMc1302135","volume":"369","author":"R Wathes","year":"2013","unstructured":"Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369(2):197\u2013198","journal-title":"N Engl J Med"},{"issue":"4","key":"6764_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.14740\/jh642","volume":"9","author":"F Furia","year":"2020","unstructured":"Furia F, Canevini MP, Federici AB, Carraro MC (2020) Unexpected neurological symptoms of ruxolitinib: A case report. J Hematol 9(4):137\u2013139","journal-title":"J Hematol"},{"issue":"1","key":"6764_CR5","first-page":"100114","volume":"2","author":"DMK Dalai","year":"2023","unstructured":"Dalai DMK, Ingle DM, Singh DG, Pandey DV, Chauhan DS, Bairwa DY (2023) A case of Tofacitinib induced mania. Psychiatry Res Case Rep 2(1):100114","journal-title":"Psychiatry Res Case Rep"},{"key":"6764_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ejphar.2015.06.060","volume":"764","author":"T Fukuyama","year":"2015","unstructured":"Fukuyama T, Tschernig T, Qi Y, Volmer DA, B\u00e4umer W (2015) Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. Eur J Pharmacol 764:278\u2013282","journal-title":"Eur J Pharmacol"},{"issue":"Pt B","key":"6764_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nbd.2016.02.007","volume":"92","author":"WB Haile","year":"2016","unstructured":"Haile WB, Gavegnano C, Tao S, Jiang Y, Schinazi RF, Tyor WR (2016) The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis 92(Pt B):137\u2013143","journal-title":"Neurobiol Dis"},{"issue":"1","key":"6764_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12032-022-01897-4","volume":"40","author":"B Goker Bagca","year":"2022","unstructured":"Goker Bagca B, Ozates NP, Biray Avci C (2022) Ruxolitinib enhances cytotoxic and apoptotic effects of Temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. Med Oncol 40(1):37","journal-title":"Med Oncol"},{"key":"6764_CR9","doi-asserted-by":"publisher","first-page":"176403","DOI":"10.1016\/j.ejphar.2024.176403","volume":"968","author":"J Min","year":"2024","unstructured":"Min J, Zheng H, Xia H, Tian X, Liang M, Zhang J et al (2024) Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-\u03baB\/MAPK signaling pathway. Eur J Pharmacol 968:176403","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"6764_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000092086","volume":"3","author":"G Castelo-Branco","year":"2006","unstructured":"Castelo-Branco G, Arenas E (2006) Function of Wnts in dopaminergic neuron development. Neurodegenerative Dis 3(1\u20132):5\u201311","journal-title":"Neurodegenerative Dis"},{"issue":"12","key":"6764_CR11","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0091270010389469","volume":"51","author":"JG Shi","year":"2011","unstructured":"Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y et al (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51(12):1644\u20131654","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"6764_CR12","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"V Srdan","year":"2013","unstructured":"Srdan V, Ruben AM, Jason G, Richard SL, Vikas G, John FD et al (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865\u20131871","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06764-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06764-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06764-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:41Z","timestamp":1771398221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06764-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6764"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06764-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7291804\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}